Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

Eiger is a biopharmaceutical company developing new antiviral agents againstnovel targets in the treatment of hepatitis.
Founded
2008
Raised
$28M
Follow us
Alexa global traffic share
Latest funding
$25,000,000
Post-IPO debt - 2017
Oxford Finance
$3,000,000
Venture capital - 2016
Team Size
2
Employees
$25,000,000 Post-IPO debt
biospace

Eiger Biopharma Completes 25 Million Debt Financing With Oxford Finance